Exelixis, Inc. Announces Revenue Results for the Fourth Quarter and Full Year 2020
January 10, 2021 at 04:00 pm
Share
Exelixis, Inc. announced revenue results for the fourth quarter and full year 2020. For the quarter, the company reported total revenues of $270 million and net product revenues of $200 million.
For the full year, the company reported total revenues of $988 million and net product revenues of $741 million.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
EXELIXIS, INC. 
